Technical analysis of GT Biopharma, Inc. (GTBP): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells.
Price Performance
| 1 month | +13.35% |
| 3 months | -39.22% |
| Year-to-date | -60.21% |
| 1 year | -60.42% |
| 3 years | -95.75% |
| 5 years | -99.87% |
52-Week Range
| 52-week High | $34.25 |
| 52-week Low | $4.91 |
| Avg Volume (90d) | 65K |
Technical Indicators
| SMA 50 | $8.00 |
| SMA 200 | $11.64 |
| 30-day Volatility (annualised) | 174.6% |
| Price vs SMA 50 | -2.3% |
| Price vs SMA 200 | -32.9% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $15.68 | |
| 2025-11 | $19.75 | +26.0% |
| 2025-12 | $19.63 | -0.6% |
| 2026-01 | $16.50 | -15.9% |
| 2026-02 | $11.95 | -27.6% |
| 2026-03 | $10.20 | -14.6% |
| 2026-04 | $7.70 | -24.5% |
| 2026-05 | $11.96 | +55.3% |
| 2026-06 | $12.24 | +2.3% |
| 2026-07 | $7.34 | -40.0% |
| 2026-08 | $7.15 | -2.6% |
| 2026-09 | $7.81 | +9.2% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $7.81 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.40 |
| EV / EBITDA | -0.48 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 2.61 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -128.11 |